fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg. - LARVOL DELTA

Cost-Utility of Fluticasone Propionate/Salmeterol and Fluticasone Propionate Monotherapy in Step-Up Treatment of Childhood Asthma. (PubMed, Pediatr Pulmonol) - "This study's findings are aligned with previous evidence on the economic value of ICS/LABA combinations, which found similar cost-effectiveness ratios for ICS/LABA therapies within accepted thresholds. Our probabilistic perspective supports FSC's potential as a feasible option in clinical practice for achieving better asthma control in children."

HEOR • Journal • Monotherapy • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

General physicians' experience and perception of symptoms control in patients of asthma changed to branded generic formulation of Salmeterol/Fluticasone in Spain: The ORIGEN study (ERS 2025) - No abstract available

Clinical • Asthma • Immunology • Respiratory Diseases

Effectiveness Salmeterol-Fluticasone and Indacaterol on FEV1/FVC Post-Tuberculosis Patient at dr. H. Abdul Moeloek Hospital Lampung Province Indonesia (ERS 2025) - No abstract available

Clinical • Infectious Disease • Respiratory Diseases • Tuberculosis

The Impact of Salmeterol and Fluticasone on Clinical Outcomes and Inflammatory Mediators in Asthma in vivo (ERS 2025) - No abstract available

Clinical data • Preclinical • Asthma • Immunology • Respiratory Diseases

The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe chronic obstructive pulmonary disease: A randomized trial (MUSIC). (PubMed, Eur Respir J) - "Fluticasone/salmeterol 500 increased sputum but not upper airway bacterial loads. ICS withdrawal was poorly tolerated in severe COPD."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Secondary Adrenal Insufficiency due to Inhaled Fluticasone Use Alone (ENDO 2025) - "Her life-long history of asthma was controlled on daily fluticasone propionate/salmeterol and albuterol as needed. She also suffered from intermittent asthma flares which required steroid courses with most recent prednisone course a year prior to presentation...She was recommended to start on hydrocortisone replacement however instead, she slowly tapered off her inhaled steroid over the course of three months...It has been better recognized that concomitant use of CYP3A4 inhibitor can cause AI such as seen in ritonavir with inhaled fluticasone or itraconazole and inhaled budesonide...Through this report, we aim to raise awareness about the potential risk of SAI associated with inhaled steroid use alone. We would like to emphasize the importance of careful clinical evaluation in those receiving long-term corticosteroid therapy regardless of formulation, and prompt recognition and treatment to prevent adrenal crisis and improve patient outcomes."

Asthma • Endocrine Disorders • Fatigue • Immunology • Nephrology • Renal Disease • Respiratory Diseases

Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler. (PubMed, JAMA Intern Med) - "Rescue medication use (albuterol and prednisone fills), emergency department visits, and hospitalizations (all-cause, respiratory-related, and pneumonia-specific) were assessed. In the cohort study of 258 557 patients (mean [SD] age, 68.9 [11.3] years; 94% male), those who switched to a fluticasone-salmeterol dry-powder inhaler had no difference in mortality (1.89% vs 1.90%; adjusted absolute difference, -0.01 percentage points [95% CI, -0.12 to 0.10 percentage points]) but had increases in all-cause hospitalizations (16.14% vs 15.64%; adjusted absolute difference, 0.49 percentage points [95% CI, 0.21-0.78 percentage points]), respiratory-related hospitalizations (3.15% vs 2.74%; adjusted absolute difference, 0.41 percentage points [95% CI, 0.27-0.55 percentage points]), and pneumonia-related hospitalizations (1.15% vs 1.03%; adjusted absolute difference, 0.12 percentage points [95% CI, 0.04-0.21 percentage points]) at 180 days after the switch compared with matched..."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Robotic tracheobronchoplasty from the perspective of anesthetic assistance: a case report (Euroanaesthesia 2025) - "History of severe, refractory asthma, complicated by tracheomalacia, using Beclometasone + Formoterol + Glycopyrronium and Salmeterol + Fluticasone.3 Salbutamol puffs were administered just before anesthetic induction, which was performed with Fentanyl, Propofol and Rocuronium...Maintenance was achieved with continuous infusion of Propofol, Remifentanil and Rocuronium. Adjuvants included Ketamine, Methadone, Magnesium Sulfate, Lidocaine and Dexmedetomidine. Tranexamic acid was administered to reduce risk of bleeding.During the surgical procedure, selective ventilation and periods of apnea were required for tracheal suturing...She was discharged 7 days later without complications. Robotic-assisted tracheobronchoplasty has been first described in the last 10 years1, and anesthesia for this procedure presents additional challenges with the use of the robotic system, the need for immobility and intermittent ventilatory maneuvers. This case demonstrates a successful approach..."

Case report • Clinical • Anesthesia • Asthma • Immunology • Respiratory Diseases

Evaluation of Lung- Function and Asthma Control in Patients With Persistent Airflow Limitation on Indacaterol/Mometasone/Glycopyrronium Dry Powder Inhaler: A Sub-group Analysis of a Phase IV Study (ATS 2025) - "All the patients were on prior ICS/LABA with Fluticasone/Salmeterol being the predominant prior medication utilized by 59 (49.1%) patients. Once daily Indacaterol/Mometasone/Glycopyrronium DPI emerged as a valuable treatment option for asthmatic patients with Persistent Airflow Limitation, providing a comprehensive approach in improving lung function and asthma control"

Clinical • P4 data • Asthma • Cough • Immunology • Respiratory Diseases

Comparative effectiveness of inhaled fluticasone propionate/salmeterol and budesonide/formoterol fixed-dose combinations in asthma control - a retrospective United States database analysis. (PubMed, Respir Med) - "FP/SAL and BUD/FOR were similarly effective for asthma control in real-world settings, while FP/SAL was generally associated with greater medication adherence, a key factor for long-term control."

HEOR • Journal • Retrospective data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Provider Perceptions of Inhaler Device Switching Following a Department of Veterans Affairs National Formulary Change (ATS 2025) - "In July 2021, the Veterans Health Administration (VA) changed its national formulary from budesonide-formoterol (Symbicort HFA), a metered-dose inhaler, to fluticasone-salmeterol (Wixela Inhub), a dry-powder inhaler. Limitations include both recall and non-response bias. Additional research is needed to understand processes used to inform patients and clinicians around formulary changes, which are increasingly common as pharmacy benefits managers seek to cut costs, and to identify opportunities for improved patient communication."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Needle in a Haystack: Diagnosing Sarcoidosis in a Patient With Silicosis (ATS 2025) - "He was managed symptomatically with fluticasone/salmeterol and albuterol rescue inhalers with advice to notify his pulmonologist of any acute changes...Prednisone therapy was initiated with a scheduled pulmonology follow up...This underscores the importance of not ruling out one diagnosis when the other is present. Comprehensive evaluation, avoidance of anchoring bias and vigilant investigation are essential for guiding informed clinical decisions for the management of any noted phenomenon."

Clinical • Cough • Gastroenterology • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • Tuberculosis

Asthma Complicated by Mycoplasma Pneumoniae: A Challenging Clinical Intersection (ATS 2025) - "Her asthma had previously been stable, managed with Advair twice daily and albuterol as needed...The patient was started on ceftriaxone and azithromycin...Conclusion It is imperative for physicians to be aware that mycoplasma is an important trigger for acute asthma exacerbation, and one should expect a slower response to standard asthma exacerbation treatment. Macrolide, along with standard care for acute asthma, helps to reduce inflammation and improve pulmonary function."

Clinical • Asthma • Bipolar Disorder • Cardiovascular • CNS Disorders • Cough • Depression • Hypertension • Immunology • Infectious Disease • Inflammation • Influenza • Mood Disorders • Novel Coronavirus Disease • Pneumonia • Psychiatry • Pulmonary Embolism • Respiratory Diseases • Respiratory Syncytial Virus Infections

Williams-Campbell Syndrome in a Pediatric Patient: A Case Report (ATS 2025) - "She is currently treated with azithromycin, fluticasone/salmeterol, and daily positive expiratory pressure physiotherapy. This case highlights WCS, a rare condition for which no specific curative treatment presently exists. Typical airway anomalies are well-identified on high-resolution CT. Preventative respiratory physiotherapy and infection control may help slow respiratory decline."

Case report • Clinical • Asthma • Bronchiectasis • Cough • Immunology • Infectious Disease • Influenza • Otorhinolaryngology • Pediatrics • Pneumonia • Pulmonary Disease • Respiratory Diseases

Clinical Outcomes After Switching From Metered-Dose Inhaler Budesonide-Formoterol to Dry-Powder Inhaler Fluticasone-Salmeterol in a Nationwide Veteran Cohort (ATS 2025) - "In July 2021, the Veterans Health Administration (VA) transitioned its preferred inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) controller from budesonide-formoterol MDI (Symbicort) to fluticasone-salmeterol DPI (Wixela Inhub). In this national cohort of veterans who switched from an MDI to a DPI controller during a national formulary transition, the DPI, Wixela Inhub, was associated with decreased use of rescue albuterol but increased use of prednisone and increases in all-cause and respiratory-related ED visits and hospitalizations."

Clinical • Clinical data • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Beyond the Mirror: A Case of Kartagener's Syndrome With Situs Inversus and Chronic Respiratory Complications in an Adult Patient (ATS 2025) - "His fluticasone propionate and salmeterol inhalation powder was discontinued to avoid potential adverse effects associated with PCD...Early diagnosis allows for tailored care, slowing disease progression and improving quality of life. Clinicians should consider PCD in patients with recurrent respiratory infections and structural abnormalities, particularly with situs inversus."

Clinical • Asthma • Bronchiectasis • Cardiovascular • Cough • Genetic Disorders • Hypertension • Immunology • Infectious Disease • Inflammation • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases

A Rare Coincidence of HMG-CoA Reductase Deficiency and Sarcoidosis Converging in One Patient (ATS 2025) - "He remained on IVIG, and was prescribed a combination inhaler with fluticasone and salmeterol to take as needed...Prior similar case reported favorable outcome using IVIG along with Rituximab...Importance:We present a rare case of IMNM in combination of pulmonary sarcoidosis, highlighting the complexities of treating multiple autoimmune conditions and its challenges. Despite them having similar treatment options including prednisone, methotrexate and IVIG, the patient had a suboptimal response with the development of medication side effect, complicating his clinical course."

Clinical • Dyslipidemia • Endocrine Disorders • Fibrosis • Gastroenterology • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Myositis • Sarcoidosis

Hidden in Plain Sight: A Rare Encounter With Pulmonary Sequestration (ATS 2025) - "Patient uses fluticasone salmeterol inhaler every alternate day and as-needed albuterol inhaler...Diagnosis in the adults is achieved through CT chest with contrast or an alternative being MR angiography, which are done to exclude any other thoracic pathologies and to see abnormal arterial supply. Treatment includes conservative management, treatment of choice is pulmonary lobectomy but recent advancements like endovascular embolization and coiling are provided as alternative management."

Asthma • CNS Disorders • Cough • Immunology • Infectious Disease • Lung Cancer • Oncology • Pneumonia • Respiratory Diseases

Diffuse Pulmonary Meningotheliomatosis and Turner's Syndrome: A Growing Area of Literature (ATS 2025) - "The patient was recommended to use a fluticasone-salmeterol inhaler...The patient was prescribed Amoxicillin-Clavulanate for ten days with recommendation to repeat CT scan in three months...Further investigation is needed to determine if exogenous hormone exposure, particularly progesterone, may be linked to the development of DPM in specific genotypes of Turner Syndrome. This case also demonstrates the need for clinicians to consider a diagnosis of DPM in patients presenting with diffuse ground glass pulmonary nodules."

Brain Cancer • Cardiovascular • Chronic Cough • CNS Tumor • Congestive Heart Failure • Cough • Heart Failure • Meningioma • Oncology • Respiratory Diseases • Solid Tumor • Turners Syndrome • CD163 • CD1a • VIM

Unmasking Hypersensitivity Pneumonitis: A Complex Case of Environmental Exposures and COVID-19 (ATS 2025) - "He tested positive for COVID-19 at that time and was treated with benzonatate and Combivent...He was doing very well on clinic follow-up 1.5 weeks after finishing his prednisone taper. He continued to take fluticasone/salmeterol, which he believes helps...However, other differentials include interstitial lung disease secondary to adalimumab, COVID-19 pneumonitis, or possible asthma exacerbation. This case underscores the importance of surveying for environmental exposures in dyspneic patients especially when symptoms are persistent despite treatment. This also highlights that respiratory viral infections, and in this scenario, COVID-19, may contribute to the development of hypersensitivity pneumonitis."

Clinical • Asthma • Cough • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Interstitial Lung Disease • Novel Coronavirus Disease • Pain • Pneumonia • Pulmonary Disease • Ulcerative Colitis

Economic Evaluation of Single-Inhaler Extrafine Beclometasone Dipropionate/formoterol fumarate/glycopyrronium (Trimbow®) in Adult Patients with Uncontrolled Asthma in Mexico (ISPOR 2025) - "The annual per-patient cost for BDP/FF/G was $3,881.34, compared to Beclometasone/Formoterol ($4,373.36), Budesonide/Formoterol ($6,098.29), Salmeterol/Fluticasone ($14,014.57), and Fluticasone/Vilanterol ($14,096.49). The extrafine SITT with BDP/FF/G is a dominant therapeutic option for adults with uncontrolled asthma in Mexico, delivering superior asthma control, significantly reducing exacerbations, and lowering annual per-patient costs compared to therapies currently used by IMSS."

Clinical • HEOR • Asthma • Immunology • Respiratory Diseases

Lung Deposition of Extrafine Versus Nonextrafine Aerosols at Low Inhalation Flow Rates in Adult Asthma Patients: A Composition Study. (PubMed, J Aerosol Med Pulm Drug Deliv) - " In this study, the lung deposition of extrafine formulations of beclomethasone dipropionate (BDP) and formoterol fumarate (FF) (pressurized metered-dose inhaler [pMDI] and dry powder inhaler [DPI], NEXThaler) was compared with that of nonextrafine formulations of fluticasone/salmeterol (FP/SAL) Diskus DPI and budesonide/formoterol (BUD/FF) Turbuhaler DPI in 10 patients...The median percentage of peripheral deposition from extrafine inhalers was above 30% with BDP/FF NEXThaler and pMDI, 5% or less with the FP/SAL Diskus at both flow rates, and ranged between 12% and 22% with the BUD/FF Turbuhaler DPI at flow rates of 30 and 40 L/min, respectively. Extrafine BDP/FF using NEXThaler and pMDI resulted in greater peripheral deposition of both the inhaled corticosteroid and long-acting beta-agonists moieties than the nonextrafine FP/SAL Discus and BUD/FF DPIs did."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A rare case of iatrogenic Cushing's syndrome (ESPE-ESE 2025) - "Personal history: In 2018 the patient was diagnosed with HIV, starting treatment with darunavir/ritonavir 800/160 mg and dolutegravir 50 mcg/day evolving to undetectable viral load; he had grade II obesity and severe and persistent asthma. In July 2022 he presented worsening asthma and was treated with meprednisone 40 mg for 7 days, budesonide/formoterol 100 mcg 2 puffs twice a day, montelukast 1 tablet/day at night, salmeterol/fluticasone 500/500 (Seretide diskus) 3 times a day and tiotropium 18 mcg/day...After stabilizing the asthmatic condition, the dose of corticosteroids was reduced: salmeterol/fluticasone 25/250 mcg 1 puff twice a day, budesonide was discontinued and hydrocortisone 10 mg/day was indicated. The antiretroviral medication had to be changed for Dolutegravir/ Tenofovir/ Lamivudine; the patient improved Cushing syndrome symptoms; zoledronic acid was prescribed for the secondary osteoporosis... Cushing syndrome triggered by inhaled corticosteroids is very..."

Clinical • Asthma • Back Pain • Cardiovascular • Cushing’s Disease • Endocrine Disorders • Genetic Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Obesity • Orthopedics • Osteoporosis • Pain • Pulmonary Arterial Hypertension • Respiratory Diseases • Rheumatology

Impact of Fluticasone Propionate and Salmeterol Combined with Pulmonary Rehabilitation on Pulmonary Function, Exercise Tolerance, and Quality of Life in Elderly Patients with Stable Chronic Obstructive Pulmonary Disease. (PubMed, Br J Hosp Med (Lond)) - "The recurrence rate in the combined treatment group was significantly lower than in the pulmonary rehabilitation alone group (p = 0.018), with no significant difference in the incidence of adverse events between the two groups (p > 0.05). Conclusion Fluticasone propionate and salmeterol inhalation combined with pulmonary rehabilitation can reduce recurrence rates, and improve pulmonary function, inflammatory status, and exercise tolerance, thereby significantly enhancing the quality of life for elderly patients with stable COPD."

HEOR • Journal • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • CXCL8 • IL6 • TNFA

ICS-LABA Fixed-Dose Combinations: Preferred Controller in 6-11-year-olds with Persistent Asthma. (PubMed, Int Arch Allergy Immunol) - "ICS-LABA fixed-dose combination therapies have been found to be more effective than ICS monotherapy in preventing asthma exacerbations in 6-11-year-old children with persistent asthma and could be recommended as the preferred controllers."

Journal • Asthma • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases